Genmab: FDA approves Horizon rare vision disorder drug

(CercleFinance.com) - The US Food and Drug Administration has approved the marketing of Horizon Therapeutics' teprotumumab, a molecule that was created by Denmark's Genmab nearly two decades ago.


The FDA has granted approval for the use of drug, under the trade name Tepezza, for the treatment of thyroid eye disease, a rare autoimmune disease associated with thyroid disease that affects the eyes.

Teprotumumab was created by Genmab under a collaboration with Roche, although the product's development is now being conducted by US-based drugmaker Horizon under a license deal.

Under the terms of the agreement, Genmab will receive mid-single digit royalties on Tepezza sales.

Copyright (c) 2020 CercleFinance.com. All rights reserved.